Bao Pharma Completes HK$1.37 Million Buyback, Treasury Shares Rise to 2.79 Million

Bulletin Express

Sep 08

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) repurchased 85,800 H-shares on 08 September 2026 via on-market transactions, paying a total of HK$1.37 million at prices ranging from HK$15.81 to HK$16.45 per share. The volume-weighted average price was HK$16.01.

Following the transaction, the company’s outstanding share count (excluding treasury shares) decreased by 0.06% to 151.54 million, while treasury shares grew to 2.79 million. Total issued shares remained unchanged at 154.33 million.

The buyback was executed under the mandate approved on 26 May 2026, which authorises the repurchase of up to 15.43 million shares. To date, Bao Pharma has repurchased 2.79 million shares, representing 1.81% of the issued share capital at the time the mandate was granted.

In line with Hong Kong Stock Exchange regulations, the company is subject to a moratorium on issuing, selling or transferring any treasury shares until 08 October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/1133093859"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133093859\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133093859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133093859","market":"hk","top_or_hot":-1,"title":"Bao Pharma Completes HK$1.37 Million Buyback, Treasury Shares Rise to 2.79 Million","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) repurchased 85,800 H-shares on 08 September 2026 via on-market transactions, paying a total of HK$1.37 million at prices ranging from HK$15.81 to HK$16.45 per share. The volume-weighted average price was HK$16.01.</p>\n<p>Following the transaction, the company’s outstanding share count (excluding treasury shares) decreased by 0.06% to 151.54 million, while treasury shares grew to 2.79 million. Total issued shares remained unchanged at 154.33 million.</p>\n<p>The buyback was executed under the mandate approved on 26 May 2026, which authorises the repurchase of up to 15.43 million shares. To date, Bao Pharma has repurchased 2.79 million shares, representing 1.81% of the issued share capital at the time the mandate was granted.</p>\n<p>In line with Hong Kong Stock Exchange regulations, the company is subject to a moratorium on issuing, selling or transferring any treasury shares until 08 October 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma Completes HK$1.37 Million Buyback, Treasury Shares Rise to 2.79 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma Completes HK$1.37 Million Buyback, Treasury Shares Rise to 2.79 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-08 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) repurchased 85,800 H-shares on 08 September 2026 via on-market transactions, paying a total of HK$1.37 million at prices ranging from HK$15.81 to HK$16.45 per share. The volume-weighted average price was HK$16.01.</p>\n<p>Following the transaction, the company’s outstanding share count (excluding treasury shares) decreased by 0.06% to 151.54 million, while treasury shares grew to 2.79 million. Total issued shares remained unchanged at 154.33 million.</p>\n<p>The buyback was executed under the mandate approved on 26 May 2026, which authorises the repurchase of up to 15.43 million shares. To date, Bao Pharma has repurchased 2.79 million shares, representing 1.81% of the issued share capital at the time the mandate was granted.</p>\n<p>In line with Hong Kong Stock Exchange regulations, the company is subject to a moratorium on issuing, selling or transferring any treasury shares until 08 October 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1133093859","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133093859","pubTimestamp":1788861804,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) repurchased 85,800 H-shares on 08 September 2026 via on-market transactions, paying a total of HK$1.37 million at prices ranging from HK$15.81 to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝医药完成137万港元回购，库存股增至279万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) repurchased 85,800 H-shares on 08 September 2026 via on-market transactions, paying a total of HK$1.37 million at prices ranging from HK$15.81 to HK$16.45 per share. The volume-weighted average price was HK$16.01.\nFollowing the transaction, the company’s outstanding share count (excluding treasury shares) decreased by 0.06% to 151.54 million, while treasury shares grew to 2.79 million. Total issued shares remained unchanged at 154.33 million.\nThe buyback was executed under the mandate approved on 26 May 2026, which authorises the repurchase of up to 15.43 million shares. To date, Bao Pharma has repurchased 2.79 million shares, representing 1.81% of the issued share capital at the time the mandate was granted.\nIn line with Hong Kong Stock Exchange regulations, the company is subject to a moratorium on issuing, selling or transferring any treasury shares until 08 October 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}